News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
270,368 Results
Type
Article (14377)
Company Profile (282)
Press Release (255709)
Multimedia
Podcasts (49)
Webinars (7)
Section
Business (80016)
Career Advice (183)
Deals (13333)
Drug Delivery (35)
Drug Development (50604)
Employer Resources (33)
FDA (5788)
Job Trends (5166)
News (145259)
Policy (10104)
Tag
Academia (921)
Accelerated approval (2)
Adcomms (12)
Allergies (52)
Alliances (21766)
ALS (68)
Alzheimer's disease (852)
Antibody-drug conjugate (ADC) (108)
Approvals (5812)
Artificial intelligence (132)
Autoimmune disease (19)
Automation (5)
Bankruptcy (105)
Best Places to Work (4576)
BIOSECURE Act (6)
Biosimilars (44)
Biotechnology (232)
Bladder cancer (59)
Brain cancer (20)
Breast cancer (161)
Cancer (1517)
Cardiovascular disease (121)
Career advice (158)
Career pathing (2)
CAR-T (121)
Cell therapy (337)
Cervical cancer (9)
Clinical research (41274)
Collaboration (562)
Compensation (275)
Complete response letters (13)
COVID-19 (1044)
CRISPR (44)
C-suite (171)
Cystic fibrosis (77)
Data (1592)
Denatured (11)
Depression (32)
Diabetes (142)
Diagnostics (1326)
Digital health (3)
Diversity (2)
Diversity, equity & inclusion (10)
Drug discovery (85)
Drug pricing (29)
Drug shortages (3)
Duchenne muscular dystrophy (91)
Earnings (30248)
Editorial (19)
Employer branding (4)
Employer resources (31)
Events (48931)
Executive appointments (471)
FDA (6557)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (510)
Gene editing (102)
Generative AI (10)
Gene therapy (260)
GLP-1 (370)
Government (1101)
Grass and pollen (2)
Guidances (66)
Healthcare (6626)
Huntington's disease (23)
IgA nephropathy (25)
Immunology and inflammation (96)
Indications (20)
Infectious disease (1110)
Inflammatory bowel disease (119)
Inflation Reduction Act (8)
Influenza (21)
Intellectual property (68)
Interviews (24)
IPO (7319)
IRA (11)
Job creations (874)
Job search strategy (149)
Kidney cancer (7)
Labor market (8)
Layoffs (216)
Leadership (3)
Legal (1401)
Liver cancer (34)
Lung cancer (207)
Lymphoma (103)
Machine learning (5)
Management (7)
Manufacturing (148)
MASH (59)
Medical device (2649)
Medtech (2650)
Mergers & acquisitions (6353)
Metabolic disorders (402)
Multiple sclerosis (53)
NASH (13)
Neurodegenerative disease (71)
Neuropsychiatric disorders (25)
Neuroscience (1271)
NextGen: Class of 2025 (2027)
Non-profit (855)
Now hiring (22)
Obesity (197)
Opinion (103)
Ovarian cancer (66)
Pain (45)
Pancreatic cancer (60)
Parkinson's disease (121)
Partnered (8)
Patents (135)
Patient recruitment (82)
Peanut (35)
People (25863)
Pharmaceutical (47)
Pharmacy benefit managers (5)
Phase I (14551)
Phase II (19197)
Phase III (12151)
Pipeline (917)
Policy (48)
Postmarket research (861)
Preclinical (6160)
Press Release (30)
Prostate cancer (63)
Psychedelics (35)
Radiopharmaceuticals (214)
Rare diseases (297)
Real estate (1429)
Recruiting (13)
Regulatory (8723)
Reports (16)
Research institute (943)
Resumes & cover letters (21)
Rett syndrome (4)
RNA editing (5)
RSV (10)
Schizophrenia (62)
Series A (99)
Series B (66)
Service/supplier (1)
Sickle cell disease (41)
Special edition (12)
Spinal muscular atrophy (117)
Sponsored (12)
Startups (1988)
State (1)
Stomach cancer (4)
Supply chain (23)
Tariffs (12)
The Weekly (37)
Vaccines (217)
Venture capitalists (32)
Weight loss (110)
Women's health (15)
Worklife (2)
Date
Today (103)
Last 7 days (556)
Last 30 days (1792)
Last 365 days (19383)
2025 (6943)
2024 (20623)
2023 (22507)
2022 (26940)
2021 (27947)
2020 (23510)
2019 (16321)
2018 (11818)
2017 (13826)
2016 (11890)
2015 (14435)
2014 (10448)
2013 (7564)
2012 (7626)
2011 (7695)
2010 (7492)
Location
Africa (154)
Alabama (43)
Alaska (2)
Arizona (54)
Arkansas (5)
Asia (17403)
Australia (2950)
California (4049)
Canada (1172)
China (373)
Colorado (152)
Connecticut (154)
Delaware (109)
Europe (37518)
Florida (491)
Georgia (121)
Idaho (16)
Illinois (247)
India (10)
Indiana (94)
Iowa (2)
Japan (80)
Kansas (63)
Kentucky (6)
Louisiana (3)
Maine (11)
Maryland (494)
Massachusetts (3216)
Michigan (72)
Minnesota (150)
Mississippi (1)
Missouri (37)
Montana (14)
Nebraska (4)
Nevada (17)
New Hampshire (14)
New Jersey (1002)
New Mexico (12)
New York (1089)
North Carolina (568)
North Dakota (5)
Northern California (1803)
Ohio (115)
Oklahoma (9)
Oregon (21)
Pennsylvania (763)
Puerto Rico (6)
Rhode Island (19)
South America (213)
South Carolina (5)
Southern California (1558)
Tennessee (25)
Texas (471)
United States (13843)
Utah (57)
Virginia (83)
Washington D.C. (31)
Washington State (359)
Wisconsin (16)
270,368 Results for "apt therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Pharm Country
Ellodi Pharmaceuticals Announces FLUTE-2 Data to be Presented at DDW 2024 with APT-1011 in Patients with Eosinophilic Esophagitis
Ellodi Pharmaceuticals, a gastroenterology-focused specialty pharmaceutical company, announced an oral presentation by Professor Evan Dellon M.D., M.P.H, at the Digestive Disease Week 2024 Annual Scientific Meeting.
May 21, 2024
·
4 min read
Deals
BiomX Announces Entry into Merger Agreement with Adaptive Phage Therapeutics and Concurrent $50 Million Financing
BiomX Inc. today announced that it has entered into a definitive merger agreement with Adaptive Phage Therapeutics, Inc. (“APT”), a U.S.-based privately-held, clinical-stage biotechnology company pioneering the development of phage-based therapies to combat bacterial infections (the “Acquisition”).
March 6, 2024
·
15 min read
Press Releases
Aptevo Therapeutics Provides Program Update for Bispecific APVO711, a PD-L1 X CD40 that Combines a Checkpoint Inhibitor and Immune Activation
May 8, 2025
·
7 min read
Press Releases
Aptevo Therapeutics $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
April 22, 2025
·
6 min read
Drug Development
Adaptive Phage Therapeutics Announces First Patient Dosed in the DANCE Trial, a Phase 1/2 Study Evaluating APT Phage Bank in Diabetic Foot Osteomyelitis
Adaptive Phage Therapeutics, Inc. (“APT”), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that the first patient has been dosed in its DFO Adaptive Novel Care Evaluation (DANCE™) trial,
May 18, 2022
·
3 min read
Press Releases
Aptevo Therapeutics Announces the Closing of $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
April 23, 2025
·
5 min read
Business
Oyster Point Pharma Announces Collaboration with Adaptive Phage Therapeutics (APT) to Target Ophthalmic Diseases
Oyster Point Pharma, Inc. announced a newly formed research collaboration with Adaptive Phage Therapeutics to leverage APT’s PhageBank™ technology for the development of potential treatments for multiple ophthalmic diseases.
June 10, 2021
·
9 min read
BioCapital
Adaptive Phage Therapeutics Announces “The AMR RAPID™ Challenge” for the Infectious Disease Research Community: Find a Bacteria Resistant to APT’s Investigational Phage Bank
Adaptive Phage Therapeutics, Inc. announced “The AMR RAPID™ Challenge” at the World AMR Congress.
September 7, 2022
·
2 min read
Press Releases
Aptevo Therapeutics $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
April 3, 2025
·
7 min read
Press Releases
Aptevo Therapeutics Reports 2024 Financial Results And Provides A Business Update
February 17, 2025
·
15 min read
1 of 27,037
Next
